The role of Staphylococcus aureus (SA) in the pathogenesis and management in atopic dermatitis is rapidly evolving. The modern understanding of SA in atopic dermatitis now includes an expanded array of virulence factors, the interplay of clonal and temporal shifts in SA populations, and host factors such as filaggrin and natural moisturizing factor. New, emerging therapies that focus on long-term, targeted elimination of SA colonization are currently under investigation (Br J Dermatol 2017;17(1)63–71). Herein, we discuss and review the latest staphylococcal and microbiome-modifying therapies including topical antibiotics, topical natural oil fatty acids, anti-SA vaccines, microbial transplantation, vitamin D supplementation, dupilumab and proposed future investigative directions.
Get full access to this article
View all access options for this article.
References
1.
NuttenS. Atopic dermatitis: global epidemiology and risk factors. Ann Nutr Metab, 2015; 66(Suppl 1):8–16.
2.
DansoM, BoitenW, van DrongelenV, et al.Altered expression of epidermal lipid bio-synthesis enzymes in atopic dermatitis skin is accompanied by changes in stratum corneum lipid composition. J Dermatol Sci, 2017; 88(1):57–66.
3.
ZhuTH, ZhuTR, TranKA, et al.Epithelial barrier dysfunctions in atopic dermatitis: a skin-gut-lung model linking microbiome alteration and immune dysregulation. Br J Dermatol, 2018; 179(3):570–581.
4.
KongHH, OhJ, DemingC, et al.Temporal shifts in the skin microbiome associated with disease flares and treatment in children with atopic dermatitis. Genome Res, 2012; 22(5):850–859.
5.
WilliamsMR, GalloRL. Evidence that human skin microbiome dysbiosis promotes atopic dermatitis. J Invest Dermatol, 2017; 137(12):2460–2461.
6.
NakatsujiT, GalloRL. The role of the skin microbiome in atopic dermatitis. Ann Allergy Asthma Immunol, 2019; 122(3):263–269.
7.
TotteJE, van der FeltzWT, HennekamM, et al.Prevalence and odds of Staphylococcus aureus carriage in atopic dermatitis: a systematic review and meta-analysis. Br J Dermatol, 2016; 175(4):687–695.
8.
MeylanP, LangC, MermoudS, et al.Skin colonization by Staphylococcus aureus precedes the clinical diagnosis of atopic dermatitis in infancy. J Invest Dermatol, 2017; 137(12):2497–2504.
9.
HarkinsCP, PettigrewKA, OravcovaK, et al.The microevolution and epidemiology of Staphylococcus aureus colonization during atopic eczema disease flare. J Invest Dermatol, 2018; 138(2):336–343.
10.
PallerAS, KongHH, SeedP, et al.The microbiome in patients with atopic dermatitis. J Allergy Clin Immunol, 2019; 143(1):26–35.
11.
JonesAL, Curran-EverettD, LeungDYM. Food allergy is associated with Staphylococcus aureus colonization in children with atopic dermatitis. J Allergy Clin Immunol, 2016; 137(4):1247–1248.e1243.
12.
LeydenJJ, MarplesRR, KligmanAM. Staphylococcus aureus in the lesions of atopic dermatitis. Br J Dermatol, 1974; 90(5):525, 530.
ChristophersE, HenselerT. Contrasting disease patterns in psoriasis and atopic dermatitis. Arch Dermatol Res, 1987; 279(Suppl):S48–S51.
15.
LesterMR, HoferMF, GatelyM, et al.Down-regulating effects of IL-4 and IL-10 on the IFN-gamma response in atopic dermatitis. J Immunol(Baltimore, Md: 1950), 1995; 154(11):6174–6181.
16.
OhmenJD, HanifinJM, NickoloffBJ, et al.Overexpression of IL-10 in atopic dermatitis. Contrasting cytokine patterns with delayed-type hypersensitivity reactions. J Immunol (Baltimore, Md: 1950), 1995; 154(4):1956–1963.
17.
HepburnL, HijnenDJ, SellmanBR, et al.The complex biology and contribution of Staphylococcus aureus in atopic dermatitis, current and future therapies. Br J Dermatol, 2017; 177(1):63–71.
18.
SimpsonEL, VillarrealM, JepsonB, et al.Patients with atopic dermatitis colonized with Staphylococcus aureus have a distinct phenotype and endotype. J Invest Dermatol, 2018; 138(10):2224–2233.
19.
HonKL, TsangYC, PongNH, et al.Clinical features and Staphylococcus aureus colonization/infection in childhood atopic dermatitis. J Dermatolog Treat, 2016; 27(3):235–240.
20.
SvejgaardE. The role of microorganisms in atopic dermatitis. Semin Dermatol, 1990; 9(4):255–261.
21.
DahlMV. Staphylococcus aureus and atopic dermatitis. Arch Dermatol, 1983; 119(10):840–846.
22.
McFaddenJP, NobleWC, CampRD. Superantigenic exotoxin-secreting potential of staphylococci isolated from atopic eczematous skin. Br J Dermatol, 1993; 128(6):631–632.
23.
SkovL, BaadsgaardO. Superantigens. Do they have a role in skin diseases? Arch Dermatol, 1995; 131(7):829–832.
24.
MorishitaY, TadaJ, SatoA, et al.Possible influences of Staphylococcus aureus on atopic dermatitis—the colonizing features and the effects of staphylococcal enterotoxins. J Br Soc Allergy Clin Immunol, 1999; 29(8):1110–1117.
25.
HjorthN, SchmidtH, ThomsenK. Fusidic acid plus betamethasone in infected or potentially infected eczema. Pharmatherapeutica, 1985; 4(2):126–131.
26.
LeverR, HadleyKAY, DowneyD, et al.Staphylococcal colonization in atopic dermatitis and the effect of topical mupirocin therapy. Br J Dermatol, 1988; 119(2):189–198.
27.
StalderJF, FleuryM, SourisseM, et al.Comparative effects of two topical antiseptics (chlorhexidine vs KMnO4) on bacterial skin flora in atopic dermatitis. Acta Derm Venereol Suppl (Stockh), 1992; 176:132–134.
28.
Sasai-TakedatsuM, KojimaT, YamamotoA, et al.Reduction of Staphylococcus aureus in atopic skin lesions with acid electrolytic water—a new therapeutic strategy for atopic dermatitis. Allergy, 1997; 52(10):1012–1016.
29.
KubotaK, MachidaI, TamuraK, et al.Treatment of refractory cases of atopic dermatitis with acidic hot-spring bathing. Acta Derm Venereol, 1997; 77(6):452–454.
30.
BrockowK, GrabenhorstP, AbeckD, et al.Effect of gentian violet, corticosteroid and tar preparations in Staphylococcus-aureus–colonized atopic eczema. Dermatology (Basel, Switzerland), 1999; 199(3):231–236.
31.
YeungM, Balma-MenaA, ShearN, et al.Identification of major clonal complexes and toxin producing strains among Staphylococcus aureus associated with atopic dermatitis. Microbes Infect, 2011; 13(2):189–197.
32.
ClausenML, EdslevSM, NorresletLB, et al.Temporal variation of Staphylococcus aureus clonal complexes in atopic dermatitis: a follow-up study. Br J Dermatol, 2019; 180(1):181–186.
33.
GeogheganJA, IrvineAD, FosterTJ. Staphylococcus aureus and atopic dermatitis: a complex and evolving relationship. Trends Microbiol, 2018; 26(6):484–497.
34.
ByrdAL, DemingC, CassidySKB, et al.Staphylococcus aureus and Staphylococcus epidermidis strain diversity underlying pediatric atopic dermatitis. Sci Transl Med, 2017; 9(397):1–12.
35.
FeuillieC, VitryP, McAleerMA, et al.Adhesion of Staphylococcus aureus to corneocytes from atopic dermatitis patients is controlled by natural moisturizing factor levels. mBio, 2018; 9(4):pii: e01184-18.
36.
OngPY, OhtakeT, BrandtC, et al.Endogenous antimicrobial peptides and skin infections in atopic dermatitis. N Engl J Med, 2002; 347(15):1151–1160.
37.
ClausenML, EdslevSM, AndersenPS, et al.Staphylococcus aureus colonization in atopic eczema and its association with filaggrin gene mutations. Br J Dermatol, 2017; 177(5):1394–1400.
38.
ClausenML, AgnerT, LiljeB, et al.Association of disease severity with skin microbiome and filaggrin gene mutations in adult atopic dermatitis. JAMA Dermatol, 2018; 154(3):293–300.
39.
BaurechtH, RuhlemannMC, RodriguezE, et al.Epidermal lipid composition, barrier integrity, and eczematous inflammation are associated with skin microbiome configuration. J Allergy Clin Immunol, 2018; 141(5):1668–1676.e1616.
40.
ChopraR, VakhariaPP, SacotteR, et al.Efficacy of bleach baths in reducing severity of atopic dermatitis: a systematic review and meta-analysis. Ann Allergy Asthma Immunol, 2017; 119(5):435–440.
41.
MaaroufM, ShiVY. Bleach for atopic dermatitis. Dermatitis, 2018; 29(3):120–126.
42.
LeungTH, ZhangLF, WangJ, et al.Topical hypochlorite ameliorates NF-κB–mediated skin diseases in mice. J Clin Invest, 2013; 123(12):5361–5370.
43.
FukuyamaT, MartelBC, LinderKE, et al.Hypochlorous acid is antipruritic and anti-inflammatory in a mouse model of atopic dermatitis. J Br Soc Allergy Clin Immunol, 2018; 48(1):78–88.
44.
SchnoppC, RingJ, MempelM. The role of antibacterial therapy in atopic eczema. Expert Opin Pharmacother, 2010; 11(6):929–936.
45.
Magdaleno-TapialJ, Martinez-DomenechA, Valenzuela-OnateC, et al.Allergic contact dermatitis to chlorhexidine in pediatric patients. Pediatr Dermatol, 2019; 36(4):540–541.
46.
RastogiS, PatelKR, SingamV, et al.Allergic contact dermatitis to personal care products and topical medications in adults with atopic dermatitis. J Am Acad Dermatol, 2018; 79(6):1028–1033.e1026.
47.
DarrigadeAS, Leaute-LabrezeC, BoraleviF, et al.Allergic contact reaction to antiseptics in very young children. J Eur Acad Dermatol Venereol, 2018; 32(12):2284–2287.
48.
BlicharzL, RudnickaL, SamochockiZ. Staphylococcus aureus: an underestimated factor in the pathogenesis of atopic dermatitis?. Postepy Dermatol Alergol, 2019; 36(1):11–17.
49.
CavalcanteFS, AbadED, LyraYC, et al.High prevalence of methicillin resistance and PVL genes among Staphylococcus aureus isolates from the nares and skin lesions of pediatric patients with atopic dermatitis. Braz J Med Biol Res, 2015; 48(7):588–594.
50.
SyedAK, ReedTJ, ClarkKL, et al.Staphlyococcus aureus phenol-soluble modulins stimulate the release of proinflammatory cytokines from keratinocytes and are required for induction of skin inflammation. Infect Immun, 2015; 83(9):3428–3437.
51.
BrauweilerAM, BinL, KimBE, et al.Filaggrin-dependent secretion of sphingomyelinase protects against staphylococcal α-toxin–induced keratinocyte death. J Allergy Clin Immunol, 2013; 131(2):421.e421–427.e422.
52.
BrauweilerAM, GolevaE, LeungDYM. Th2 cytokines increase Staphylococcus aureus alpha toxin-induced keratinocyte death through the signal transducer and activator of transcription 6 (STAT6). J Invest Dermatol, 2014; 134(8):2114–2121.
53.
NakamuraY, OscherwitzJ, CeaseKB, et al.Staphylococcus δ-toxin induces allergic skin disease by activating mast cells. Nature, 2013; 503(7476):397–401.
54.
WoodfordN, Afzal-ShahM, WarnerM, et al.In vitro activity of retapamulin against Staphylococcus aureus isolates resistant to fusidic acid and mupirocin. J Antimicrob Chemother, 2008; 62(4):766–768.
55.
GentryDR, RittenhouseSF, McCloskeyL, et al.Stepwise exposure of Staphylococcus aureus to pleuromutilins is associated with stepwise acquisition of mutations in rplC and minimally affects susceptibility to retapamulin. Antimicrob Agents Chemother, 2007; 51(6):2048–2052.
56.
KircikLH. Efficacy and tolerability of retapamulin 1% ointment for the treatment of infected atopic dermatitis: a pilot study. J Drugs Dermatol, 2012; 11(7):858–860.
57.
PreussHG, EchardB, EnigM, et al.Minimum inhibitory concentrations of herbal essential oils and monolaurin for gram-positive and gram-negative bacteria. Mol Cell Biochem, 2005; 272(1–2):29–34.
58.
Verallo-RowellVM, DillagueKM, Syah-TjundawanBS. Novel antibacterial and emollient effects of coconut and virgin olive oils in adult atopic dermatitis. Dermatitis, 2008; 19(6):308–315.
59.
PastagiaM, SchuchR, FischettiVA, et al.Lysins: the arrival of pathogen-directed anti-infectives. J Med Microbiol, 2013; 62(Pt 10):1506–1516.
60.
TotteJ, de WitJ, PardoL, et al.Targeted anti-staphylococcal therapy with endolysins in atopic dermatitis and the effect on steroid use, disease severity and the microbiome: study protocol for a randomized controlled trial (MAAS trial). Trials, 2017; 18(1):404.
61.
HerpersB, BadouxP, PietersmaF, et al.Specific lysis of methicillin susceptible and resistant Staphylococcus aureus by the endolysin Staphefekt SA.100 TM. Paper presented at the 24th European Congress of Clinical Microbiology and Infectious Diseases (ECCMID); May 10-13, 2014; Barcelona, Spain.
62.
MartinH, Laborel-PreneronE, FraysseF, et al.Aquaphilus dolomiae extract counteracts the effects of cutaneous S. aureus secretome isolated from atopic children on CD4+ T cell activation. Pharm Biol, 2016; 54(11):2782–2785.
63.
BianchiP, TheunisJ, CasasC, et al.Effects of a new emollient-based treatment on skin microflora balance and barrier function in children with mild atopic dermatitis. Pediatr Dermatol, 2016; 33(2):165–171.
64.
GuenicheA, KnaudtB, SchuckE, et al.Effects of nonpathogenic gram-negative bacterium Vitreoscilla filiformis lysate on atopic dermatitis: a prospective, randomized, double-blind, placebo-controlled clinical study. Br J Dermatol, 2008; 159(6):1357–1363.
65.
HakanssonJ, RingstadL, UmerskaA, et al.Characterization of the in vitro, ex vivo, and in vivo efficacy of the antimicrobial peptide DPK-060 used for topical treatment. Front Cell Infect Microbiol, 2019; 9:174.
66.
NordahlEA, RydengardV, MorgelinM, et al.Domain 5 of high molecular weight kininogen is antibacterial. J Biol Chem, 2005; 280(41):34832–34839.
67.
SchmidtchenA, PasupuletiM, MorgelinM, et al.Boosting antimicrobial peptides by hydrophobic oligopeptide end tags. J Biol Chem, 2009; 284(26):17584–17594.
68.
A randomized, double-blinded placebo-controlled study to investigate antimicrobial efficacy and safety following topical application of DPK-060. Available at: https://ClinicalTrials.gov/show/NCT01522391 Accessed July28, 2019.
69.
FowlerVGJr., ProctorRA. Where does a Staphylococcus aureus vaccine stand?. Clin Microbiol Infect, 2014; 20(Suppl 5):66–75.
70.
ProctorRA. Challenges for a universal Staphylococcus aureus vaccine. Clin Infect Dis, 2012; 54(8):1179–1186.
71.
LaceyKA, GeogheganJA, McLoughlinRM. The role of Staphylococcus aureus virulence factors in skin infection and their potential as vaccine antigens. Pathogens, 2016; 5(1):22.
72.
Safety and efficacy of SA4Ag vaccine in adults having elective open posterior spinal fusion procedures with multilevel instrumentation. Available at: https://ClinicalTrials.gov/show/NCT02388165 Accessed July31, 2019.
BegierE, SeidenDJ, PattonM, et al.SA4Ag, a 4-antigen Staphylococcus aureus vaccine, rapidly induces high levels of bacteria-killing antibodies. Vaccine, 2017; 35(8):1132–1139.
75.
SchmidtCS, WhiteCJ, IbrahimAS, et al.NDV-3, a recombinant alum-adjuvanted vaccine for Candida and Staphylococcus aureus, is safe and immunogenic in healthy adults. Vaccine, 2012; 30(52):7594–7600.
76.
LevyJ, LiciniL, HaeltermanE, et al.Safety and immunogenicity of an investigational 4-component Staphylococcus aureus vaccine with or without AS03B adjuvant: results of a randomized phase I trial. Hum Vaccin Immunother, 2015; 11(3):620–631.
77.
LandrumML, LalaniT, NiknianM, et al.Safety and immunogenicity of a recombinant Staphylococcus aureus alpha-toxoid and a recombinant Panton-Valentine leukocidin subunit, in healthy adults. Hum Vaccin Immunother, 2017; 13(4):791–801.
78.
ZhuYY, LiJX, ZengH, et al.Safety, tolerability, and preliminary immunogenicity of a recombinant Staphylococcus aureus vaccine (RSAV) in healthy adults between 18 and 65 years in China: study protocol for a randomized, double-blind, placebo-controlled, phase 1 trial. J Public Health Emerg, 2017; 1(2):25.
79.
UdompataikulM, HuajaiS, ChalermchaiT, et al.The effects of oral Vitamin D supplement on atopic dermatitis: a clinical trial with Staphylococcus aureus colonization determination. J Med Assoc Thailand, 2015; 98(Suppl 9):S23–S30.
MylesIA, EarlandNJ, AndersonED, et al.First-in-human topical microbiome transplantation with Roseomonas mucosa for atopic dermatitis. JCI Insight, 2018; 3(9).
82.
NakatsujiT, ChenTH, NaralaS, et al.Antimicrobials from human skin commensal bacteria protect against Staphylococcus aureus and are deficient in atopic dermatitis. Sci Transl Med, 2017; 9(378):eaah4680.
83.
Evaluation of the kinetic properties of an autologous microbiome transplant in adult atopic dermatitis patients. https://ClinicalTrials.gov/show/NCT02144142. Accessed August3, 2019.
NissenM, MarshallH, RichmondP, et al.A randomized phase I study of the safety and immunogenicity of three ascending dose levels of a 3-antigen Staphylococcus aureus vaccine (SA3Ag) in healthy adults. Vaccine, 2015; 33(15):1846–1854.
88.
ScullyIL, TimofeyevaY, KeeneyD, et al.Demonstration of the preclinical correlate of protection for Staphylococcus aureus clumping factor a in a murine model of infection. Vaccine, 2015; 33(41):5452–5457.
SheppardDC, YeamanMR, WelchWH, et al.Functional and structural diversity in the Als protein family of Candida albicans. J Biol Chem, 2004; 279(29):30480–30489.
92.
HataTR, KotolP, JacksonM, et al.Administration of oral vitamin D induces cathelicidin production in atopic individuals. J Allergy Clin Immunol, 2008; 122(4):829–831.
93.
SearingDA, LeungDY. Vitamin D in atopic dermatitis, asthma and allergic diseases. Immunol Allergy Clin North Am, 2010; 30(3):397–409.
94.
HendricksAJ, MillsBW, ShiVY. Skin bacterial transplant in atopic dermatitis: knowns, unknowns and emerging trends. J Dermatol Sci, 2019; 95(2):56–61.
95.
MylesIA, WilliamsKW, ReckhowJD, et al.Transplantation of human skin microbiota in models of atopic dermatitis. JCI Insight, 2016; 1(10).
GandhiNA, BennettBL, GrahamNMH, et al.Targeting key proximal drivers of type 2 inflammation in disease. Nat Rev Drug Discov, 2015; 15:35.
98.
Bath-HextallFJ, BirnieAJ, RavenscroftJC, et al.Interventions to reduce Staphylococcus aureus in the management of atopic eczema: an updated Cochrane review. Br J Dermatol, 2010; 163(1):12–26.
